We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fibrinogen-Albumin Ratio Correlated to Ankylosing Spondylitis Disease Activity

By LabMedica International staff writers
Posted on 23 Mar 2020
Print article
Image: Sacroiliac joint biopsy specimen of a 29 year old male patient with ankylosing spondylitis. The biopsy specimen shows a subchondral cellular infiltrate partly invading the cartilage. Fibroblasts and activated lymphocytes are seen in the infiltrate. In between are areas of calcification and bone formation (Photo courtesy of Professor J. Braun).
Image: Sacroiliac joint biopsy specimen of a 29 year old male patient with ankylosing spondylitis. The biopsy specimen shows a subchondral cellular infiltrate partly invading the cartilage. Fibroblasts and activated lymphocytes are seen in the infiltrate. In between are areas of calcification and bone formation (Photo courtesy of Professor J. Braun).
Ankylosing spondylitis (AS) is a systematic inflammatory autoimmune disease that primarily involves the spine and sacroiliac joints. Typically the joints where the spine joins the pelvis are also affected and occasionally other joints such as the shoulders or hips are involved. Back pain is a characteristic symptom of AS, and it often comes and goes.

Some simple and cost-effective inflammatory indicators for AS, such as neutrophils to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR) and monocytes to lymphocytes ratio (MLR) have been explored. Fibrinogen (Fib) is a critical factor involved in the coagulation system, which has been reported to be increased in AS patients compared with controls and significantly correlated with C-reactive protein (CRP).

Rheumatologists and Immunologists at the Guangdong Second Provincial General Hospital (Guangzhou, China) performed a retrospective study that included 135 AS patients that visited from March 2016 and June 2019. Seventy-six age- and sex-matched healthy subjects from the Department of Physical Examination Center who had no evidence of illness were enrolled in the control group at the same period.

Clinical characteristics included human leukocyte antigen (HLA)-B27 status, number of white blood cells (WBCs), lymphocytes, neutrophils, monocytes, platelets (PLT), red blood cell distribution width (RDW), Fib, albumin (ALB), globulin (GLB), CRP and erythrocyte sedimentation rate (ESR) level were collected. neutrophil to lymphocyte ratio (NLR), monocyte to lymphocytes ratio (MLR), platelet-lymphocyte ratio (PLR) and fibrinogen to albumin ratio (FAR) were calculated. All the peripheral venous blood samples were taken after an overnight fast of at least eight hours.

The investigators reported that AS patients showed higher FAR levels than the controls. FAR was also increased in active group of AS patients than those in inactive group. Spearman analyses showed that FAR was positively related with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in AS patients. ROC curve analyses revealed that the AUC of FAR was higher than ALB and Fib. In addition, the optimal cutoff value of FAR for AS diagnosis was 78.84, with a specificity of 88.2% and sensitivity of 77.0%. Logistical regression analyses showed that FAR (odds ratio = 13.091) was a predictor for AS disease activity.

The authors concludes that their study showed that FAR was increased in AS patients and significantly positively correlated with AS disease activity. High FAR was revealed as an adverse predictor for the disease activity in AS patients. The study indicated that FAR may be a novel biomarker for reflecting disease activity in AS patients. The study was published on February 26, 2020 in the journal Clinica Chimica Acta.

Related Links:
Guangdong Second Provincial General Hospital

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.